Established in 2020, OBIGEN Pharma, a subsidiary of OBI Pharma, is the first biotech startup in Taiwan specializing in the research, development, production, and manufacturing of Botulinum toxin. Their type A botulinum toxin, OBI-858, originates from an API plant adhering to the PIC/s GMP standards in the Zhubei Biomedical Science Park and a high-security sterile drug product plant in the Tainan Science Park. 

Guided by diligent efforts, OBIGEN develops and produces stable quality products, contributing to advancing the entire medical industry. With a dedicated focus on innovation and vitality, OBIGEN actively forges international partnerships to globally launch the exceptional Taiwan toxin.

OBIGEN PHARMA

Org chart

Teams

Offices

OBIGEN PHARMA

Org chart

Teams

Offices

Related companies